AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobson, J. G.
Right arrow Articles by Drach, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobson, J. G.
Right arrow Articles by Drach, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 1888-1894, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Nonnucleoside Pyrrolopyrimidines with a Unique Mechanism of Action against Human Cytomegalovirus

Jennie G. Jacobson,1 Thomas E. Renau,1,2,dagger M. Reza Nassiri,1,Dagger Dominica G. Sweier,1 Julie M. Breitenbach,1 Leroy B. Townsend,2 and John C. Drach1,2,*

Department of Biologic and Materials Sciences, School of Dentistry,1 and Interdepartmental Graduate Program in Medicinal Chemistry, College of Pharmacy,2 University of Michigan, Ann Arbor, Michigan 48109-1078

Received 1 December 1998/Returned for modification 23 February 1999/Accepted 13 May 1999

Based upon a prior study which evaluated a series of nonnucleoside pyrrolo[2,3-d]pyrimidines as inhibitors of human cytomegalovirus (HCMV), we have selected three active analogs for detailed study. In an HCMV plaque-reduction assay, compounds 828, 951, and 1028 had 50% inhibitory concentrations (IC50s) of 0.4 to 1.0 µM. Similar results were obtained when 828 and 951 were examined by HCMV enzyme-linked immunosorbent assay (IC50s = 1.9 and 0.4 µM, respectively) and when 828 was tested in a viral DNA-DNA hybridization assay (IC50 = 1.3 µM). In yield-reduction assays with a low multiplicity of infection (MOI), all three compounds caused multiple log10 reductions in virus titer, and the activities of these compounds were comparable to the activity of ganciclovir (GCV; IC90 = 0.2 µM). In contrast to the reduction of viral titers by GCV, the reduction of viral titers by 828, 951, and 1028 decreased with increasing MOI. Cytotoxicity in human foreskin fibroblasts and KB cells ranged from 32 to >100 µM. In addition, 828 (the only compound tested) was less toxic against human bone marrow progenitor cells than GCV. Time-of-addition and time-of-removal studies established that the three pyrrolopyrimidines inhibited HCMV replication before GCV had an effect on viral DNA synthesis but after viral adsorption. Compound 828 was equally effective against GCV-sensitive and GCV-resistant HCMV clinical isolates. Combination studies with 828 and GCV showed that the effects of the two compounds on HCMV were additive but not synergistic. Taken together, the data indicate that these pyrrolopyrimidines target a viral protein that is required in an MOI-dependent manner and that is expressed early in the HCMV replication cycle.

* Corresponding author. Mailing address: School of Dentistry, University of Michigan, 1011 N. University Ave., Ann Arbor, MI 48109-1078. Phone: (734) 763-5579. Fax: (734) 764-7406. E-mail: jcdrach{at}umich.edu.

dagger Present address: Microcide Pharmaceuticals, Inc., Mountainview, CA 94043.

Dagger Present address: Lake Erie College of Osteopathic Medicine, Erie, PA 16509.

Antimicrobial Agents and Chemotherapy, August 1999, p. 1888-1894, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.